Coming of Age: Targeting Cyclin K in Cancers
Cells · 2023
DOI: 10.3390/cells12162044 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Yi Xiao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Eppley Institute for Research in Cancer and Allied Diseases, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE …. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Institutes of Health (NIH).
Abstract (Originalsprache)
Cyclins and cyclin-dependent kinases (CDKs) play versatile roles in promoting the hallmarks of cancer. Therefore, cyclins and CDKs have been widely studied and targeted in cancer treatment, with four CDK4/6 inhibitors being approved by the FDA and many other inhibitors being examined in clinical trials. The specific purpose of this review is to delineate the role and therapeutic potential of Cyclin K in cancers. Studies have shown that Cyclin K regulates many essential biological processes, including the DNA damage response, mitosis, and pre-replicative complex assembly, and is critical in both cancer cell growth and therapeutic resistance. Importantly, the druggability of Cyclin K has been demonstrated in an increasing number of studies that identify novel opportunities for its use in cancer treatment. This review first introduces the basic features and translational value of human cyclins and CDKs. Next, the discovery, phosphorylation targets, and related functional significance of Cyclin K-CDK12/13 complexes in cancer are detailed. This review then provides a summary of current Cyclin K-associated cancer studies, with an emphasis on the available Cyclin K-targeting drugs. Finally, the current knowledge gaps regarding the potential of Cyclin K in cancers are discussed, along with interesting directions for future investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eppley Institute for Research in Cancer and Allied Diseases, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
ORCID-Profile: Yi Xiao, Jixin Dong
Förderung
- NCI NIH HHS
- Institutes of Health (NIH)
Zitieren
APA
Xiao, Y., & Dong, J. (2023). Coming of Age: Targeting Cyclin K in Cancers. Cells. https://doi.org/10.3390/cells12162044
Vancouver
Xiao Y, Dong J. Coming of Age: Targeting Cyclin K in Cancers. Cells. 2023. doi:10.3390/cells12162044
BibTeX
@article{Xiao2023,
author = {Xiao, Yi and Dong, Jixin},
title = {Coming of Age: Targeting Cyclin K in Cancers},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12162044}
}
EUVIMED